NCT04539613

Brief Summary

despite the large number of papers published on COH protocols comparing the efficiency of different exogenous gonadotropins, no confirmed protocol exists, and it is not quite clear which is superior to the others.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 31, 2020

Completed
1 day until next milestone

Study Start

First participant enrolled

September 1, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 7, 2020

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2021

Completed
Last Updated

September 7, 2020

Status Verified

August 1, 2020

Enrollment Period

4 months

First QC Date

August 31, 2020

Last Update Submit

August 31, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • fertility outcomes (pregnancy rate, abortion and live birth rate) in IVF patients.

    (pregnancy rate, abortion and live birth rate) in IVF patients.

    5months

Study Arms (2)

group1

Group 1(50 case) which will receive hp FSH (fostimon ibsa) (150 IU per ampoule)will be started on day 2 of menstruation and then after six days, HMG (meriofert ibsa), 150 Iu, s.c) will be added

Drug: HPFSH & HMG

group2

Group 2(50 case) will be treated with recombinant FSH alone (Gonal-F) (150 IU per ampoule)

Interventions

. Various gonadotropin preparations

Also known as: rec-F.S.H
group1

Eligibility Criteria

Age20 Years - 35 Years
Sexfemale(Gender-based eligibility)
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Normal ovulatory function and normal semen analysis

You may qualify if:

  • Aged 20-35 yr, male factor, 2-Tubal or unexplained infertility, 3-regular menstruation cycle between 21 and 35 days, 4-Normal function of uterus according to hysterosalpingography, hysteroscopy or transvaginal ultrasonography, 5-Normal ovaries according to transvaginal ultrasonography during past 6 months prior to study and compatible with normal adnexa and 6-Normal ovarian anatomy, and serum FSH level less than 8 IU/l All women showed no recognizable endometriosis according to symptoms and clinical examination in transvaginal ultrasonography or diagnostic laparoscopy. 7-7-All women have a history of unexplained infertility 8-Normal ovulatory function and normal semen analysis according to the World Health Organization criteria .

You may not qualify if:

  • Patients with other ovulation disorders such as hypo and hypergonadotropic, hypogonadism, hyperprolactinemia.
  • Thyroid disorders. 3-Ovarian or adrenal neoplasms. 4-Cushing syndrome. 5-previous history of systemic diseases such as endocrine and metabolic disorders.
  • Previous history of inappropriate ovarian response to stimulation with gonadotropins (poor responders).
  • Prior history of more than 3 unsucce

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

El neel

Minya, Egypt

RECRUITING

Related Publications (1)

  • Kamel RM. The onset of human parturition. Arch Gynecol Obstet. 2010 Jun;281(6):975-82. doi: 10.1007/s00404-010-1365-9. Epub 2010 Feb 3.

    PMID: 20127346BACKGROUND

Central Study Contacts

Amna Abdel sabour

CONTACT

kareem shaheen

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Controlled Ovarian Hyperstimulation (COH) With Sequential HPFSH & HMG Versus Rec-F.S.H Alone in ICSI Cycle

Study Record Dates

First Submitted

August 31, 2020

First Posted

September 7, 2020

Study Start

September 1, 2020

Primary Completion

January 1, 2021

Study Completion

February 1, 2021

Last Updated

September 7, 2020

Record last verified: 2020-08

Locations